What does it take to be a driver of the biosimilar revolution?

Given that copycat biologics are a relatively new part of the healthcare landscape, especially in the USA, the blueprint on how to become a successful biosimilars company is yet to established.

What are the optimal discounts to offer on the reference products to deliver savings for healthcare systems while protecting margins? What marketing techniques will ensure widespread take-up in the US market? What do physicians need to be assured of biosimilarity and interchangeability?

All these questions and more are yet to be answered, but the identity of the companies that will answer them is becoming clearer as copies of some of the world’s leading biologics reach more and more patients in the world’s major markets.